Recombinant Human ICOS (aa 21-134) His-tag Protein, CF

When Recombinant Human B7‑H2 Fc Chimera (Catalog # 165‑B7) is immobilized at 0.5 μg/mL, Recombinant Human ICOS (Catalog #9865‑CS) binds with an ED50 of 25‑125 ng/mL.

2 μg/lane of Recombinant Human ICOS was resolved with SDS-PAGEunder reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 20-34 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human ICOS (aa 21-134) His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human B7-H2 Fc Chimera (Catalog # 165-B7) at 0.5 µg/mL (100 µL/well) can bind Recombinant Human ICOS with an ED₅₀ of 25-125 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human ICOS protein
  

  Human ICOS (Glu21-Gln134) Accession # Q9Y6W8-1	HHHHHH	IEGR
  N-terminus		C-terminus

• Accession #: Q9Y6W8-1
• N-terminal Sequence: Glu21
• Structure / Form: Noncovalent Homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 14 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 20-34 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage:
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human ICOS (aa 21-134) His-tag Protein, CF

• Activation-inducible lymphocyte immunomediatory molecule
• AILIM
• AILIMCD278
• CD278 antigen
• CD278
• CRP-1
• CVID1
• ICOS
• inducible costimulator
• inducible T-cell costimulator
• inducible T-cell co-stimulator
• MGC39850

Background

Inducible co-stimulator (ICOS), also called AILIM (activation-inducible lymphocyte immunomediatory molecule) and CRP-1 (CD28-related protein-1), is a member of the growing CD28 family of immune costimulatory receptors (1). Other family members are CD28, CTLA-4 and PD-1 (2, 4). Human ICOS is a homodimeric type I transmembrane protein consisting of 199 amino acids (aa) with a putative 20 aa signal sequence, a 121 aa extracellular domain, a 23 aa transmembrane region, and a 35 aa cytoplasmic domain. ICOS shares approximately 39% amino acid similarity with CD28 and CTLA-4. Human and mouse ICOS share approximately 72% amino acid identity. ICOS is expressed on most CD45RO+ cells (3). ICOS expression is up-regulated within approximately 24-48 hours of activation on Th primed cells (4, 6). B7-H2, a member of the B7 family of co-stimulatory ligands, has been identified as the ICOS ligand (4, 5). The B7-H2/ICOS interaction appears to play roles in T cell dependent B cell activation and Th differentiation (5, 7).

1. Aicher, A. et al. (2000) J. Immunol. 164:4689.
2. Coyle, A.J. et al. (2000) Immunity 13:95.
3. Coyle, A.J. and Gutierrez-Ramos, J.C. (2001) Nat. Immunol. 2:203.
4. Gonzalo, J.A. et al. (2001) J. Immunol. 166:1.
5. Hutloff, A. et al. (1999) Nature 397:263.
6. Mages, H.W. et al. (2000) Eur. J. Immunol. 30:1040.
7. Yoshinaga, S.K. et al. (1999) Nature 402:827.

Bioinformatics

• Uniprot:
  • Q9Y6W8-1()